Targeting Interleukin 13 for the Treatment of Atopic Dermatitis [PDF]
Pharmaceutics, 2023 Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj +3 more sources
Interleukin-13 (IL-13)-A Pleiotropic Cytokine Involved in Wound Healing and Fibrosis. [PDF]
Int J Mol Sci, 2023 The liver, as a central metabolic organ, is systemically linked to metabolic–inflammatory diseases. In the pathogenesis of the metabolic syndrome, inflammatory and metabolic interactions between the intestine, liver, and adipose tissue lead to the ...
Roeb E.
europepmc +2 more sources
Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]
Viruses, 2020 Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
John Foerster, Aleksandra Molęda
doaj +4 more sources
Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. [PDF]
Dermatol Ther (Heidelb), 2023 IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13.
Okragly AJ +6 more
europepmc +2 more sources
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis. [PDF]
Front Med (Lausanne), 2023 Recent evidence suggests that interleukin (IL)-13 is a crucial cytokine involved in the pathogenesis of atopic dermatitis (AD). It is a central driver of type-2 T-helper inflammation and is overexpressed in lesional skin of AD patients.
Napolitano M +4 more
europepmc +2 more sources
Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid [PDF]
Annals of Medicine, 2023 Aim: Bullous pemphigoid (BP) is an organ-specific autoimmune bullous disease characterized by autoantibodies that target the cellular adhesion molecules BP180 and BP230.
Fangyuan Chen +4 more
doaj +2 more sources
Interleukin-13 and its receptor are synaptic proteins involved in plasticity and neuroprotection. [PDF]
Nat Commun, 2023 Immune system molecules are expressed by neurons, yet their functions are often unknown. We have identified IL-13 and its receptor IL-13Ra1 as neuronal, synaptic proteins in mouse, rat, and human brains, whose engagement upregulates the phosphorylation ...
Li S +21 more
europepmc +2 more sources
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
Frontiers in Pharmacology, 2019 Approximately 5–10% of asthmatic patients worldwide suffer from severe asthma. Experimental and clinical studies have demonstrated that IL-13 is an important cytokine in chronic airways inflammation.
Giancarlo Marone +14 more
doaj +2 more sources
The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. [PDF]
Front ImmunolChronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly a type 2 inflammatory disease associated with type 2 (T2) cell responses and epithelial barrier, mucociliary, and olfactory dysfunction.
Bachert C +8 more
europepmc +2 more sources
Interleukin‐4 and interleukin‐13 evoke scratching behaviour in mice [PDF]
Experimental Dermatology, 2019 AbstractPersistent and relapsing itch commonly manifests in inflammatory skin disorders such as atopic dermatitis (AD). AD pathogenesis is driven by interleukin‐4 (IL‐4) and interleukin‐13 (IL‐13). Dupilumab, a monoclonal antibody blocking the action of IL‐4 and IL‐13 effectively reduces the symptoms of AD and itch.
Michelle Campion +5 more
openaire +5 more sources